Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06311942
Status:
RECRUITING
Last Update Posted:
2024-05-07
First Post:
2024-03-09
Brief Title:
Triple vs Dual Adjuvant Therapy Following Liver Resection for HCC
Sponsor:
Chen Xiaoping
Organization:
Tongji Hospital
Study Overview
Official Title:
Effectiveness of Triple Versus Dual Adjuvant Therapy in VETC-positive Population Following Liver Resection for HCC a Prospective Multicenter Cohort Study
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Vessels that encapsulate tumor clusters VETC is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition EMT and VETC-positive patients have a higher rate of postoperative recurrence What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored
Detailed Description:
Previous studies have identified VETC as a new metastatic pattern independent of EMT that may be associated with immunosuppression as well as poor prognosis Multiple retrospective studies find higher rates of postoperative recurrence distant metastasis in VETC-positive patients How to improve surgical prognosis in VETC-positive patients needs to be explored In recent years adjuvant immunotherapy sintilimab and adjuvant immunotherapy combined with targeted therapy TA have been shown to be effective in improving the surgical prognosis There are no published studies on how to improve prognosis for VETC-positive population One of our unpublished retrospective studies found that VETC-positive patients receiving PD-1 monoclonal antibody was not effective in improving prognosis however PD-1 inhibitor combined with lenvatinib reduces recurrences significantly In addition some studies have also found that postoperative adjuvant hepatic artery infusion chemotherapy HAIC is also potentially useful in improving surgical prognosis It is not clear whether triple therapy can further reduce recurrence in these tumors which have highly aggressive characteristics
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None